Beckman's Access Ostase blood test gets US FDA go-ahead:
This article was originally published in Clinica
Beckman Coulter has received US FDA 510(k) clearance to market what it claims is the first automated serum-based blood test in the US that can help manage osteoporosis and Paget's disease. The Access Ostase assay, which is available on the company's Access Immunoassay system, is less expensive than bone mineral density tests that are traditionally used to measure the effectiveness of osteoporosis therapy, said the company.
You may also be interested in...
Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).